The FDA expanded the approval of the SONU Band to include the treatment of patients aged 12 years and older with moderate to severe nasal congestion due to allergic or nonallergic rhinitis ...

TUESDAY, June 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is ...

It's the world's first twice-yearly shot and was shown in trials to be 96% effective at preventing HIV. Advocates call it a gamechanger.

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence rates compared to other PrEP medications and with minimal side effects.

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

Even though the trial has concluded, Haddock said, he plans to continue receiving lenacapavir injections twice a year, and he hopes the FDA approval will help raise awareness of HIV prevention tools.

The company announced that the US FDA approved Yeztugo ® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)’s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to ...

Sometimes, a nasal steroid spray can help with congestion. “Using a 24-hour decongestant, such as oxymetazoline, the day of the flight can also help,” he adds.

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management.

The FDA clears for marketing a robotic surgery device used for surgery, characterized as the first of its kind.